Lexeo Therapeutics (LXEO) Stock Price, News & Analysis

Company Overview

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations.

The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Founded in 2017, Lexeo is based in New York and conducts research and clinical development in the United States. As a clinical-stage company, it focuses on advancing its pipeline rather than marketing approved therapies.

Key Stats

• Today's Range: $2.82 to $3.05
• 50-Day Range: $2.63 to $4.89
• 52-Week Range: $2.55 to $10.99
• Volume: 1.72 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $238.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.43
• Consensus Rating: Buy

Lexeo Therapeutics Stock Analysis - MarketRank™

Lexeo Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 348th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Lexeo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Lexeo Therapeutics has a consensus price target of $16.43, representing about 464.6% upside from its current price of $2.91.

Amount of Analyst Coverage

Lexeo Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lexeo Therapeutics are expected to decrease in the coming year, from ($1.22) to ($1.44) per share.

Price to Book Value per Share Ratio

Lexeo Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.19% of the float of Lexeo Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lexeo Therapeutics has a short interest ratio ("days to cover") of 12.73, which indicates bearish sentiment.

Change versus previous month

Short interest in Lexeo Therapeutics has recently decreased by 2.94%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lexeo Therapeutics does not currently pay a dividend.

Dividend Growth

Lexeo Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.79

News Sentiment

Lexeo Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Lexeo Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for LXEO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Lexeo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lexeo Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,240.00 in company stock.

Percentage Held by Insiders

2.00% of the stock of Lexeo Therapeutics is held by insiders.

Percentage Held by Institutions

60.67% of the stock of Lexeo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/12/2026
• Next Earnings (Estimated): 12/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LXEO
• Previous Symbol: NASDAQ:LXEO
• CIK: 1907108
• Web: www.lexeotx.com
• Phone: 212-547-9879
• Fax: N/A
• Employees: 59
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Lexeo Therapeutics: $16.43
• High Price Target: $25.00
• Low Price Target: $9.00
• Potential Upside/Downside: +464.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$99.96 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.85%
• Return on Assets: -38.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.89
• Quick Ratio: 13.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.38 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 82,050,000
• Free Float: 80,405,000
• Market Cap: $238.77 million
• Optionable: Optionable
• Beta: 1.64